[Bone scintigraphy with 99mTc-pyrophosphate: pharmokinetics of the substance and clinical experiences with the scintigraphy].
Kinetics and clinical studies of bone scintiscanning with 99mTc-pyrophosphate in 92 patients with certified diagnosis allowed the following conclusions: 1. After i.v. injection 99mTc-pyrophosphate is distributed in 3 compartments, from which it is cleared with biological half-lives of 32.7 minutes, 5.1 hours and 22.54 hours respectively. The relative size of these compartments is 1 : 3 : 6. After application of the substance, an initially high renal excretion with a consecutive exponential drop can be observed. The optimal period for scintigraphic studies seems therefore to be from 3-6 hrs, as at this time there is still an adequate activity in bone structures, while the low background activity yields a good contrast on scintiscans. 2. The clinical results of bone scintigraphy with 99mTc-pyrophosphate with 88.6% correct diagnoses can be considered as "very good". This feature can partly be attributed to an improved correlation of radiographic and scintigraphic images by the use of a specially designed, combined radiographic-photoscanning detector system. 3. Preliminary results concerning the quantitative uptake of 99mTc-pyrophosphate in fractures of the extremities suggest, that the quantitative analyses of the registered data can provide valuable prognostic information in traumatic, inflammatory and neoplastic bone lesions.
D001847:Bone Diseases / Q000175:diagnosis* / Q000000981:diagnostic imaging; D001859:Bone Neoplasms / Q000175:diagnosis; D001842:Bone and Bones / Q000378:metabolism; D011756:Diphosphates; D050723:Fractures, Bone / Q000175:diagnosis; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D011859:Radiography; D011877:Radionuclide Imaging; D013667:Technetium / Q000378:metabolism
D011756:Diphosphates; D013667:Technetium
Knochenszintigraphie mit 99mTc-Pyrophosphat: Pharmakokinetik der Substanz und klinische Erfahrungen bei der Szintigraphie